EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT05189509

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05189509
Other papers using this trial's data
  • Tenecteplase Plus Butyphthalide for Stroke Within 4.5-6 Hours of Onset (EXIT-BT): a Phase 2 Study Translational stroke research, 2025-06 DOI, PubMed 38238620

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05189509. Randomized; single masking; primary purpose treatment. Start 2022-02-11 (actual); primary completion 2022-09-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT)
Condition
Stroke, Ischemic
Intervention (Drug)
TNK-Tissue Plasminogen Activator
Lead sponsor
General Hospital of Shenyang Military Region (class: other)

Record details

Record id
cardio:ct-nct05189509
Content hash
0d753995d11cf9a07726e7a34dacc59060c7ffc183f42f22834da0de1417fc92